AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06126575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant dihydrochloride
Description: A single oral dose of 200 mg elacestrant (2 x 100 mg tablets).
Study NCT06466603 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: GABA Probiotic Dose 1
Description: Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 6-week product use period with a total of 42 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. After the 6-week study product use period, all participants will be given the option to continue using GABA Probiotic for an additional 4 weeks. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
Study NCT06466603 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: GABA Probiotic Dose 2
Description: Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 6-week product use period with a total of 42 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. After the 6-week study product use period, all participants will be given the option to continue using GABA Probiotic for an additional 4 weeks. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
Study NCT06466603 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Placebo Group
Description: Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 6-week product use period with a total of 42 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. After the 6-week study product use period, all participants will be given the option to continue using GABA Probiotic for an additional 4 weeks. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
Study NCT05496231 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV9 High formulation
Description: 3 doses of a high formulation investigational adjuvanted HPV9 vaccine intramuscularly (IM) on Day 1, Month 2, and Month 6.
Study NCT05496231 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV9 Medium formulation
Description: 3 doses of a medium formulation investigational adjuvanted HPV9 vaccine administered IM on Day 1, Month 2, and Month 6.
Study NCT05496231 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV9 Low formulation
Description: 3 doses of a low formulation investigational adjuvanted HPV9 vaccine administered IM on Day 1, Month 2, and Month 6.
Study NCT05496231 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil 9
Description: 3 doses of the marketed HPV vaccine (Gradasil 9) administered IM on Day 1, Month 2, and Month 6.
Study NCT05130463 — intervention group
Intervention type: DRUG
Intervention: empagliflozin/linagliptin
Description: tablet
Study NCT06324370 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Virgin Coconut Oil
Description: Virgin Coconut Oil (VCO) will be administered with 240 mL water and standardized food during dosing periods.While the participant is standing up, each dose will be administered orally with at least 240 mL of water and standardized meal after an overnight fast of at least 10 hours on each occasion. The time of dosing will be recorded to the nearest minute in the case report form (CRF).~No other liquid or solid food intake is permitted during this time. Fluid intake will be ad libitum 4 hours post-dose. There will be a washout interval of 7 days between the single- and multiple-dose studies.~Participants will not be permitted to take any prescribed medication or over-the-counter products (including vitamins and herbal supplements) within 14 days prior to dosing or during the course of the study.
Study NCT06544148 — intervention group
Intervention type: DEVICE
Intervention: Electrical impedance tomography
Description: In addition to routine critical care with a pulmonary artery catheter already in place (PAC), an electrical impedance tomography (EIT) belt will be placed in patients enrolled in this study. Data will be analyzed offline and clinical trajectory and/or decisions will not be impacted by this additional monitoring. EIT is a non-invasive, safe, and radiation-free medical imaging modality.
Study NCT05811637 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates Exercise
Description: The program will be applied with the Pilates exercises every week. All patients were evaluated before and after the treatment (6 weeks).
Study NCT05811637 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Rehabilitation
Description: The program will be applied with the progression of the supervised rehabilitation in the 4th week
Study NCT05784597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-OncoFAP administration
Description: All patients will receive a single intravenous bolus administration of 250 MBq (225 - 275 MBq)
Study NCT04769986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Mindfulness-Relapse Prevention (mMBRP)
Description: Mindfulness Coach 2.0 is a mobile application designed by the VA's National Center for PTSD. The app provides: (a) psychoeducational topics related to mindfulness; (b) audio-guided mindfulness exercises; (c) self-assessment using the Five Facet Mindfulness Questionnaire (d) a journal to track mindfulness practice sessions; (e) goal setting and tracking; (f) personal, customizable reminders; and (g) immediate access to support and crisis resources. We will enhance Mindfulness Coach with MBRP content by adding information about the triangle of awareness to understand connections among thoughts, sensations, and emotions, and specific meditations of sober breathing space and urge surfing to deal with cravings. We will add additional MBRP-specific modules. Participants will be asked to complete the intervention during 8 weeks, with two to three modules per week. After a beta test with 20 veterans, feedback will be used to refine the app for the national randomized clinical trial (RCT).
Study NCT04769986 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise/healthy eating mobile app
Description: Participants in the control condition will be asked to download an exercise/healthy eating mobile app and use it for 8 weeks. Similar to Mindfulness Coach, the app will have specialized self-management guides that follow a guide-per-week format, educational videos that teach diet and exercise strategies, and a diary to track diet and exercise progress.
Study NCT06048705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3901961
Description: GSK3901961 was administered.
Study NCT06048705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide was administered as lymphodepleting chemotherapy.
Study NCT06048705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine was administered as lymphodepleting chemotherapy.
Study NCT06456541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Extensively Hydrolyzed Formula
Description: Experimental powder formula
Study NCT06456541 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Extensively Hydrolyzed Formula
Description: Placebo powder formula
Study NCT05302609 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SclerFIX
Description: Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical cord lining membrane allograft used as substitute for scleral graft in reinforcement of scleral thinning.
Study NCT06565663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MaPGAS Decision Aid
Description: This intervention involves a novel, web-based decision aid tool specifically designed to support transgender and non-binary individuals assigned female at birth in making informed decisions about Metoidioplasty and Phalloplasty Gender Affirming Surgeries (MaPGAS). The tool includes comprehensive information on surgical options, risks, benefits, and medical illustrations to aid in aligning surgical decisions with the individual's personal values and goals.
Study NCT06530303 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: Tumor Infiltrating Lymphocytes (TIL) IV
Study NCT06530303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
Study NCT06530303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered as an intravenous (IV) infusion for five days.
Study NCT06530303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
Study NCT06530303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion
Study NCT04736121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resin microspheres containing yttrium-90 (Y-90)
Description: Biocompatible resin microspheres are an injectable permanent implant and preferentially placed into the distal microvascular supply of tumors to provide direct irradiation of tissue and destruction of the microvascular bed. Spheres contain yttrium-90 (Y-90) and are a size between 20 and 60 microns in diameter.
Study NCT05857878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1815368
Description: BI 1815368
Study NCT05857878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo
Study NCT06171737 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Decision Aid
Description: The American College of Cardiology decision aid: Treatment Options for Severe Aortic Stenosis for patients deciding between Tavi and Surgery
Study NCT06171737 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shared Decision Making Skills Training
Description: 60-minute online training session that will provide practical tips, interactive case studies and tools for conducting shared decision making conversations covering core competencies
Study NCT04636437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine 100 Mg
Description: Participants will receive 100 mg tablet by mouth daily with or without food.
Study NCT04636437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide/emtricitabine
Description: NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
Study NCT04636437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir alafenamide/lamivudine
Description: NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
Study NCT04636437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Integrase strand transfer inhibitors
Description: NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
Study NCT04636437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir disproxil fumarate/emtricitabine
Description: NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
Study NCT04636437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir disproxil fumarate/lamivudine
Description: NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
Study NCT06035510 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein supplement
Description: Participants are given Isolated whey protein supplement in evening before surgery and first day of post operation to compare with standard operative care on postoperative outcomes after gynecological cancer surgery
Study NCT05230407 — intervention group
Intervention type: OTHER
Intervention: Visual analog scale (VAS) assesment of pain
Description: Post operation VAS score will be assessed before discharge from hospital and 24 hours post operation
Study NCT05861752 — intervention group
Intervention type: BEHAVIORAL
Intervention: Treatment as usual
Description: both groups will undergo a psychiatric assessment including interviews, impulsivity tests and fill out questionnaires and leave blood samples. The clinical population will be followed regarding treatment as usual
Study NCT06541249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: MTX has recently been identified as a dose-dependent JAK/STAT pathway inhibitor. 15mg will be given once a week orally.
Study NCT04012710 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopy
Description: Conventional abdominal laparoscopy
Study NCT04012710 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vNOTES
Description: Transvaginal natural orifice transluminal endoscopic surgery for salpingo-oophorectomy
Study NCT06222294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate
Description: Loading dose: 0.08mg/kg Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.1-0.2mg/kg/h
Study NCT06222294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Medium and Long Chain Fat Emulsion Injection
Description: Loading dose: 0.3-0.5mg/kg Maintenance dose: IV Propofol Medium and Long Chain Fat Emulsion Injection, dose range 0.3-4.0mg/kg/h, increment or decrement of 0.3-0.6mg/kg/h
Study NCT05726383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iscador*P
Description: Iscador P given for 2 cycles with follow up imaging done every 2 cycles. If imaging is negative patient remains on study for 13 cycles. If new lesion is found, then patient is off study.
Study NCT05802537 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based exergame program
Description: The home-based exergame program was conducted using the Nintendo Switch and Ring Fit Adventure program at participants' homes. The program included a 10-minute warm-up, 30 minutes of main exercise, and a 10-minute cool-down, lasting a total of 50 minutes per session. Sessions were held three times per week for eight weeks. The exercises targeted lower extremity strength, balance, and flexibility and included yoga, leg exercises (e.g., squats, knee lifts), and other activities performed in a gamified virtual environment. Participants received guidance on using the console, and family members were involved to support proper execution of the exercises.
Study NCT05802537 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online education on fall prevention and musculoskeletal health management
Description: The online education intervention consisted of weekly sessions conducted for 50 minutes over an eight-week period, focusing on fall prevention and musculoskeletal health management. Participants joined the sessions via a video-conference platform. The content covered education on aging, musculoskeletal disorders, fall prevention strategies, and understanding falls and fractures. These sessions aimed to enhance participants' awareness and knowledge, thereby helping them adopt preventive behaviors.
Study NCT05118529 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Mobilization to chair
Study NCT05118529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care
Description: Mobilization to chair
Study NCT05776459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC102 gel
Description: Drug: AC102 Single intratympanic injection
Study NCT05776459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Active comparator: Prednisolone Tablets taken daily by mouth
Study NCT05776459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Tablets
Description: Placebo Tablets taken daily by mouth
Study NCT05776459 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo gel
Description: Placebo Single intratympanic injection
Study NCT05710458 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 25 gauge 20,000 cpm Hypervit Dual Blade
Description: Vitrectomy blade with increased cutting rate to 20,000 cut/min
Study NCT05710458 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 25 gauge 10,000 cpm Ultravit Vitrectomy Cutter
Description: Existing Vitrectomy blade with cutting rate 10,000 cut/min
Study NCT05109104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAP UnScented
Description: Sunscreen lip balm.
Study NCT05109104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAP Herbal Mint
Description: Sunscreen lip balm.
Study NCT05109104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAP Mountain Berry
Description: Sunscreen lip balm.
Study NCT05109104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPF Standard Sunscreen
Description: SPF Standard (7 percent \[%\] Padimate-O and 3% Oxybenzone)
Study NCT04704661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy
Study NCT04704661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04704661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Given PO
Study NCT04704661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study NCT04704661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT04704661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT04704661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT04704661 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: Given IV
Study NCT06477042 — intervention group
Intervention type: OTHER
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ-12) score
Description: Change in quality-of-life score assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) between the 2-month early visit and inclusion in the poor-prognosis group.
Study NCT03760315 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood mNGS (IDSeqTM Ultra); blood Culture
Description: take blood samples for mNGS and Culture at the same time in sepsis patients. No intervention on the treatment of the patients.
Study NCT05248464 — intervention group
Intervention type: OTHER
Intervention: The Patient Dignity Inventory instrument (PDI)
Description: The PDI is an instrument made up of 25 items integrated into 5 factors that include: symptoms, existential anguish, dependency, peace of mind, and social support, prior to its application, adaptation, and validation will performer
Study NCT05248464 — intervention group
Intervention type: OTHER
Intervention: WHOQOL-BREF (quality of life) instrument
Description: The WHOQOL-BREF is a self-report questionnaire which assesses 4 domains of quality of life (QOL): physical health, psychological health, social relationships, and environment, it consists of 24 items.
Study NCT04881162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NOVIS Transcarotid Neuroprotection System (NPS)
Description: The NOVIS Transcarotid Neuroprotection System (NPS) is intended to provide transcarotid vascular access and embolic protection
Study NCT05954962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone 200 MG
Description: The patients in the study group will administer oral natural micronized progesterone capsules from day 1 of ovarian stimulation instead of antagonist (ganirelix) subcutaneaous injections from day 5-6 of stimulation.
Study NCT05954962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganirelix Acetate
Description: The patients in the control group will administer subcutaneaous injections of ganirelix from day 5-6 of stimulation as per currently used protocol.